<s id="wsj_0690.1"> 34
2 	 0 	 N/N 	 1 	 regulators Federal
2 	 1 	 N/N 	 1 	 regulators drug
2 	 4 	 S[adj]\NP 	 1 	 regulators concerned <XB>
2 	 20 	 (S[dcl]\NP)/S[dcl] 	 1 	 regulators say
4 	 5 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 2 	 concerned over
7 	 5 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 3 	 reports over
7 	 6 	 N/N 	 1 	 reports British
8 	 7 	 N/S[em] 	 1 	 that reports
9 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 diabetics have
9 	 11 	 S[pt]\NP 	 1 	 diabetics died <XB>
9 	 13 	 ((S[ng]\NP)/PP)/PP 	 1 	 diabetics shifting <XB>
10 	 8 	 S[em]/S[dcl] 	 1 	 have that
11 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 died have
11 	 12 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 2 	 died after
13 	 12 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 3 	 shifting after
14 	 13 	 ((S[ng]\NP)/PP)/PP 	 3 	 from shifting
15 	 14 	 PP/(S[adj]\NP) 	 1 	 animal from
16 	 13 	 ((S[ng]\NP)/PP)/PP 	 2 	 to shifting
18 	 16 	 PP/NP 	 1 	 insulin to
18 	 17 	 N/N 	 1 	 insulin human-based
21 	 22 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 they are
21 	 23 	 (S[ng]\NP)/NP 	 1 	 they considering <XB>
22 	 20 	 (S[dcl]\NP)/S[dcl] 	 2 	 are say
23 	 22 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 considering are
25 	 23 	 (S[ng]\NP)/NP 	 2 	 study considering
25 	 24 	 NP[nb]/N 	 1 	 study a
27 	 26 	 (S[to]\NP)/(S[b]\NP) 	 2 	 see to
28 	 27 	 (S[b]\NP)/S[qem] 	 2 	 if see
30 	 29 	 N/N 	 1 	 deaths similar
30 	 31 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 deaths have
30 	 32 	 S[pt]\NP 	 1 	 deaths occurred <XB>
31 	 28 	 S[qem]/S[dcl] 	 1 	 have if
32 	 31 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 occurred have
32 	 33 	 (S\NP)\(S\NP) 	 2 	 occurred here
<\s>
<s id="wsj_0690.2"> 20
3 	 0 	 NP[nb]/N 	 1 	 reports The
3 	 1 	 N/N 	 1 	 reports United
3 	 2 	 N/N 	 1 	 reports Kingdom
3 	 4 	 S[dcl]\NP 	 1 	 reports came
4 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 came from
8 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 Toseland from
8 	 6 	 N/N 	 1 	 Toseland Dr.
8 	 7 	 N/N 	 1 	 Toseland Patrick
10 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 head from
10 	 11 	 (NP\NP)/NP 	 1 	 head of
10 	 14 	 (NP\NP)/NP 	 1 	 head at
13 	 11 	 (NP\NP)/NP 	 2 	 chemistry of
13 	 12 	 N/N 	 1 	 chemistry clinical
15 	 16 	 (NP[nb]/N)\NP 	 2 	 Guy 's
17 	 14 	 (NP\NP)/NP 	 2 	 Hospital at
17 	 16 	 (NP[nb]/N)\NP 	 1 	 Hospital 's
17 	 18 	 (NP\NP)/NP 	 1 	 Hospital in
19 	 18 	 (NP\NP)/NP 	 2 	 London in
<\s>
<s id="wsj_0690.3"> 31
3 	 0 	 (S/S)/NP 	 2 	 interview In
3 	 1 	 NP[nb]/N 	 1 	 interview a
3 	 2 	 N/N 	 1 	 interview telephone
7 	 6 	 N/N 	 1 	 Toseland Dr.
7 	 8 	 (S[dcl]\NP)/S[dcl] 	 1 	 Toseland said
8 	 0 	 (S/S)/NP 	 1 	 said In
8 	 4 	 S/S 	 1 	 said Friday
10 	 9 	 NP[nb]/N 	 1 	 number the
10 	 11 	 (NP\NP)/NP 	 1 	 number of
10 	 20 	 (S[pt]\NP)/NP 	 2 	 number seen <XU>
10 	 23 	 (S[dcl]\NP)/NP 	 1 	 number was
15 	 11 	 (NP\NP)/NP 	 2 	 deaths of
15 	 12 	 N/N 	 1 	 deaths sudden
15 	 14 	 N/N 	 1 	 deaths unexplained
15 	 16 	 (NP\NP)/NP 	 1 	 deaths of
17 	 16 	 (NP\NP)/NP 	 2 	 diabetics of
18 	 19 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 he had
18 	 20 	 (S[pt]\NP)/NP 	 1 	 he seen <XB>
20 	 19 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 seen had
20 	 21 	 ((S\NP)\(S\NP))/N 	 2 	 seen this
22 	 21 	 ((S\NP)\(S\NP))/N 	 3 	 year this
23 	 8 	 (S[dcl]\NP)/S[dcl] 	 2 	 was said
24 	 23 	 (S[dcl]\NP)/NP 	 2 	 17 was
24 	 25 	 (NP\NP)/PP 	 1 	 17 compared
26 	 25 	 (NP\NP)/PP 	 2 	 with compared
28 	 26 	 PP/NP 	 1 	 two with
28 	 27 	 N/N 	 1 	 two just
28 	 29 	 (NP\NP)/NP 	 1 	 two in
30 	 29 	 (NP\NP)/NP 	 2 	 1985 in
<\s>
<s id="wsj_0690.4"> 26
1 	 0 	 (N/N)/(S[asup]\NP) 	 2 	 least At
2 	 0 	 (N/N)/(S[asup]\NP) 	 1 	 six At
2 	 3 	 (NP\NP)/NP 	 1 	 six of
2 	 6 	 S[dcl]\NP 	 1 	 six occurred
5 	 3 	 (NP\NP)/NP 	 2 	 deaths of
5 	 4 	 NP[nb]/N 	 1 	 deaths the
6 	 7 	 ((S\NP)\(S\NP))/NP 	 2 	 occurred among
6 	 25 	 (S[dcl]\S[dcl])\NP 	 1 	 occurred said
9 	 8 	 (N/N)/(N/N) 	 2 	 young relatively
10 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 diabetics among
10 	 9 	 N/N 	 1 	 diabetics young
10 	 11 	 (NP\NP)/(S[dcl]\NP) 	 1 	 diabetics who
10 	 12 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 diabetics had <XB>
10 	 13 	 ((S[pt]\NP)/PP)/PP 	 1 	 diabetics switched <XB>
12 	 11 	 (NP\NP)/(S[dcl]\NP) 	 2 	 had who
13 	 12 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 switched had
13 	 19 	 ((S\NP)\(S\NP))/NP 	 2 	 switched within
14 	 13 	 ((S[pt]\NP)/PP)/PP 	 3 	 from switched
15 	 14 	 PP/NP 	 1 	 animal from
16 	 13 	 ((S[pt]\NP)/PP)/PP 	 2 	 to switched
18 	 16 	 PP/NP 	 1 	 insulin to
18 	 17 	 N/N 	 1 	 insulin human
22 	 19 	 ((S\NP)\(S\NP))/NP 	 3 	 year within
22 	 20 	 NP[nb]/N 	 1 	 year the
22 	 21 	 N/N 	 1 	 year past
24 	 25 	 (S[dcl]\S[dcl])\NP 	 2 	 he said
<\s>
<s id="wsj_0690.5"> 30
2 	 0 	 N/N 	 1 	 Sobel Dr.
2 	 1 	 N/N 	 1 	 Sobel Solomon
2 	 19 	 (S[dcl]\NP)/S[dcl] 	 1 	 Sobel said
4 	 5 	 (NP\NP)/NP 	 1 	 director of
4 	 11 	 (NP\NP)/NP 	 1 	 director for
4 	 19 	 (S[dcl]\NP)/S[dcl] 	 1 	 director said
10 	 5 	 (NP\NP)/NP 	 2 	 products of
10 	 6 	 N/N 	 1 	 products metabolism
10 	 8 	 N/N 	 1 	 products endrocrine
10 	 9 	 N/N 	 1 	 products drug
14 	 11 	 (NP\NP)/NP 	 2 	 Food for
14 	 12 	 NP[nb]/N 	 1 	 Food the
14 	 13 	 N/N 	 1 	 Food U.S.
17 	 11 	 (NP\NP)/NP 	 2 	 Administration for
17 	 12 	 NP[nb]/N 	 1 	 Administration the
17 	 13 	 N/N 	 1 	 Administration U.S.
17 	 16 	 N/N 	 1 	 Administration Drug
21 	 20 	 N/N 	 1 	 officials FDA
21 	 22 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 officials have
21 	 23 	 (S[pt]\NP)/NP 	 1 	 officials discussed <XB>
22 	 19 	 (S[dcl]\NP)/S[dcl] 	 2 	 have said
23 	 22 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 discussed have
23 	 29 	 (S\NP)\(S\NP) 	 2 	 discussed intensively
25 	 24 	 N/N 	 1 	 Toseland Dr.
25 	 26 	 (NP[nb]/N)\NP 	 2 	 Toseland 's
27 	 23 	 (S[pt]\NP)/NP 	 2 	 findings discussed
27 	 26 	 (NP[nb]/N)\NP 	 1 	 findings 's
29 	 28 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 intensively fairly
<\s>
<s id="wsj_0690.6"> 36
1 	 2 	 (S[dcl]\NP[thr])/(S[pt]\NP) 	 1 	 there have
2 	 0 	 (S/S)/S[dcl] 	 2 	 have While
3 	 2 	 (S[dcl]\NP[thr])/(S[pt]\NP) 	 2 	 been have
5 	 3 	 (S[pt]\NP)/NP 	 2 	 reports been
5 	 4 	 NP[nb]/N 	 1 	 reports no
5 	 6 	 (NP\NP)/NP 	 1 	 reports of
10 	 6 	 (NP\NP)/NP 	 2 	 deaths of
10 	 7 	 N/N 	 1 	 deaths similar
10 	 8 	 N/N 	 1 	 deaths sudden
10 	 9 	 N/N 	 1 	 deaths unexplained
10 	 11 	 (NP\NP)/NP 	 1 	 deaths among
12 	 11 	 (NP\NP)/NP 	 2 	 diabetics among
12 	 13 	 (NP\NP)/NP 	 1 	 diabetics in
15 	 13 	 (NP\NP)/NP 	 2 	 U.S. in
15 	 14 	 NP[nb]/N 	 1 	 U.S. the
18 	 17 	 N/N 	 1 	 Sobel Dr.
18 	 19 	 (S[dcl]\NP)/S[dcl] 	 1 	 Sobel said
19 	 0 	 (S/S)/S[dcl] 	 1 	 said While
21 	 20 	 NP[nb]/N 	 1 	 FDA the
21 	 22 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 FDA plans
21 	 24 	 (S[b]\NP)/NP 	 1 	 FDA examine <XB>
21 	 30 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 FDA is <XU>
21 	 31 	 (S[ng]\NP)/NP 	 1 	 FDA considering <XU>
22 	 19 	 (S[dcl]\NP)/S[dcl] 	 2 	 plans said
23 	 22 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to plans
24 	 23 	 (S[to]\NP)/(S[b]\NP) 	 2 	 examine to
26 	 25 	 N/N 	 1 	 Toseland Dr.
26 	 27 	 (NP[nb]/N)\NP 	 2 	 Toseland 's
28 	 24 	 (S[b]\NP)/NP 	 2 	 evidence examine
28 	 27 	 (NP[nb]/N)\NP 	 1 	 evidence 's
30 	 19 	 (S[dcl]\NP)/S[dcl] 	 2 	 is said
31 	 30 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 considering is
34 	 31 	 (S[ng]\NP)/NP 	 2 	 study considering
34 	 32 	 NP[nb]/N 	 1 	 study its
34 	 33 	 N/N 	 1 	 study own
34 	 35 	 NP\NP 	 1 	 study here
<\s>
<s id="wsj_0690.7"> 46
1 	 0 	 N/N 	 1 	 Toseland Dr.
1 	 6 	 (S[dcl]\NP)/S[dcl] 	 1 	 Toseland said
4 	 3 	 NP[nb]/N 	 1 	 toxicologist a
4 	 6 	 (S[dcl]\NP)/S[dcl] 	 1 	 toxicologist said
7 	 8 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 he was
7 	 9 	 ((S[ng]\NP)/PP)/NP 	 1 	 he preparing <XB>
7 	 18 	 (S[ng]\NP)/NP 	 1 	 he raising <XB>
8 	 6 	 (S[dcl]\NP)/S[dcl] 	 2 	 was said
9 	 8 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 preparing was
11 	 9 	 ((S[ng]\NP)/PP)/NP 	 3 	 article preparing
11 	 10 	 NP[nb]/N 	 1 	 article an
12 	 9 	 ((S[ng]\NP)/PP)/NP 	 2 	 for preparing
17 	 12 	 PP/NP 	 1 	 journal for
17 	 13 	 NP[nb]/N 	 1 	 journal a
17 	 14 	 N/N 	 1 	 journal British
17 	 15 	 N/N 	 1 	 journal forensic
17 	 16 	 N/N 	 1 	 journal medical
20 	 18 	 (S[ng]\NP)/NP 	 2 	 possibility raising
20 	 19 	 NP[nb]/N 	 1 	 possibility the
21 	 20 	 N/S[em] 	 1 	 that possibility
23 	 22 	 NP[nb]/N 	 1 	 deaths the
23 	 24 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 deaths may
23 	 26 	 S[pt]\NP 	 1 	 deaths occurred <XB>
24 	 21 	 S[em]/S[dcl] 	 1 	 may that
25 	 24 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 have may
26 	 25 	 (S[b]\NP)/(S[pt]\NP) 	 2 	 occurred have
26 	 27 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 occurred after
29 	 28 	 N/N 	 1 	 insulin human
29 	 30 	 (S[dcl]\NP)/NP 	 1 	 insulin blunted
30 	 27 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 blunted after
33 	 30 	 (S[dcl]\NP)/NP 	 2 	 signs blunted
33 	 31 	 N/N 	 1 	 signs critical
33 	 32 	 N/N 	 1 	 signs warning
33 	 34 	 (S[ng]\NP)/NP 	 1 	 signs indicating <XB>
35 	 34 	 (S[ng]\NP)/NP 	 2 	 hypoglycemia indicating
35 	 42 	 (NP\NP)/(S[dcl]\NP) 	 1 	 hypoglycemia which
35 	 43 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 hypoglycemia can <XB>
35 	 44 	 (S[b]\NP)/NP 	 1 	 hypoglycemia kill <XB>
40 	 34 	 (S[ng]\NP)/NP 	 2 	 sugar indicating
40 	 38 	 N/N 	 1 	 sugar low
40 	 39 	 N/N 	 1 	 sugar blood
40 	 42 	 (NP\NP)/(S[dcl]\NP) 	 1 	 sugar which
40 	 43 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 sugar can <XB>
40 	 44 	 (S[b]\NP)/NP 	 1 	 sugar kill <XB>
43 	 42 	 (NP\NP)/(S[dcl]\NP) 	 2 	 can which
44 	 43 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 kill can
45 	 44 	 (S[b]\NP)/NP 	 2 	 diabetics kill
<\s>
<s id="wsj_0690.8"> 12
3 	 0 	 NP[nb]/N 	 1 	 signs The
3 	 1 	 N/N 	 1 	 signs usual
3 	 2 	 N/N 	 1 	 signs warning
3 	 4 	 (NP\NP)/NP 	 1 	 signs of
3 	 6 	 (S[dcl]\NP)/NP 	 1 	 signs include
5 	 4 	 (NP\NP)/NP 	 2 	 hypoglycemia of
7 	 6 	 (S[dcl]\NP)/NP 	 2 	 sweating include
9 	 6 	 (S[dcl]\NP)/NP 	 2 	 anxiety include
11 	 6 	 (S[dcl]\NP)/NP 	 2 	 cramps include
<\s>
<s id="wsj_0690.9"> 20
2 	 0 	 (S/S)/NP 	 2 	 warning With
2 	 1 	 N/N 	 1 	 warning proper
4 	 5 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 diabetics can
4 	 7 	 ((S[b]\NP)/PP)/NP 	 1 	 diabetics raise <XB>
4 	 15 	 (S[ng]\NP)/NP 	 1 	 diabetics eating <XB>
5 	 0 	 (S/S)/NP 	 1 	 can With
7 	 5 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 raise can
7 	 6 	 (S\NP)/(S\NP) 	 2 	 raise easily
7 	 14 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 2 	 raise by
10 	 7 	 ((S[b]\NP)/PP)/NP 	 3 	 sugar raise
10 	 8 	 NP[nb]/N 	 1 	 sugar their
10 	 9 	 N/N 	 1 	 sugar blood
11 	 7 	 ((S[b]\NP)/PP)/NP 	 2 	 to raise
13 	 11 	 PP/NP 	 1 	 levels to
13 	 12 	 N/N 	 1 	 levels safe
15 	 14 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 3 	 eating by
16 	 15 	 (S[ng]\NP)/NP 	 2 	 sugar eating
19 	 15 	 (S[ng]\NP)/NP 	 2 	 food eating
19 	 18 	 N/N 	 1 	 food sugary
<\s>
<s id="wsj_0690.10"> 23
2 	 0 	 NP[nb]/N 	 1 	 data The
2 	 1 	 N/N 	 1 	 data anecdotal
2 	 4 	 (S[dcl]\NP)/S[em] 	 1 	 data shows
4 	 3 	 (S\NP)/(S\NP) 	 2 	 shows certainly
4 	 22 	 (S[dcl]\S[dcl])\NP 	 1 	 shows said
5 	 4 	 (S[dcl]\NP)/S[em] 	 2 	 that shows
6 	 7 	 (NP\NP)/NP 	 1 	 some of
6 	 10 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 some were
6 	 12 	 (S[adj]\NP)/PP 	 1 	 some aware <XB>
9 	 7 	 (NP\NP)/NP 	 2 	 people of
9 	 8 	 NP[nb]/N 	 1 	 people the
10 	 5 	 S[em]/S[dcl] 	 1 	 were that
10 	 11 	 (S\NP)\(S\NP) 	 2 	 were not
12 	 10 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 aware were
13 	 12 	 (S[adj]\NP)/PP 	 2 	 of aware
16 	 13 	 PP/NP 	 1 	 onset of
16 	 14 	 NP[nb]/N 	 1 	 onset the
16 	 15 	 N/N 	 1 	 onset rapid
16 	 17 	 (NP\NP)/NP 	 1 	 onset of
18 	 17 	 (NP\NP)/NP 	 2 	 hypoglycemia of
21 	 20 	 N/N 	 1 	 Toseland Dr.
21 	 22 	 (S[dcl]\S[dcl])\NP 	 2 	 Toseland said
<\s>
<s id="wsj_0690.11"> 47
4 	 0 	 (S/S)/NP 	 2 	 Institutes At
4 	 1 	 NP[nb]/N 	 1 	 Institutes the
4 	 2 	 N/N 	 1 	 Institutes U.S.
4 	 3 	 N/N 	 1 	 Institutes National
4 	 5 	 (NP\NP)/NP 	 1 	 Institutes of
6 	 5 	 (NP\NP)/NP 	 2 	 Health of
11 	 8 	 N/N 	 1 	 Silverman Dr.
11 	 9 	 N/N 	 1 	 Silverman Robert
11 	 10 	 N/N 	 1 	 Silverman E.
11 	 20 	 (S[dcl]\NP)/S[dcl] 	 1 	 Silverman said
13 	 14 	 (NP\NP)/NP 	 1 	 chief of
13 	 20 	 (S[dcl]\NP)/S[dcl] 	 1 	 chief said
18 	 14 	 (NP\NP)/NP 	 2 	 branch of
18 	 15 	 NP[nb]/N 	 1 	 branch the
18 	 16 	 N/N 	 1 	 branch diabetes
18 	 17 	 N/N 	 1 	 branch program
20 	 0 	 (S/S)/NP 	 1 	 said At
22 	 21 	 NP[nb]/N 	 1 	 evidence no
22 	 23 	 (NP\NP)/NP 	 1 	 evidence of
22 	 28 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 evidence had
22 	 29 	 S[pt]\NP 	 1 	 evidence shown <XB>
25 	 23 	 (NP\NP)/NP 	 2 	 deaths of
25 	 24 	 N/N 	 1 	 deaths unexpected
25 	 26 	 (NP\NP)/NP 	 1 	 deaths from
27 	 26 	 (NP\NP)/NP 	 2 	 hypoglycemia from
28 	 20 	 (S[dcl]\NP)/S[dcl] 	 2 	 had said
29 	 28 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 shown had
29 	 30 	 (S\NP)\(S\NP) 	 2 	 shown up
29 	 31 	 ((S\NP)\(S\NP))/NP 	 2 	 shown in
33 	 31 	 ((S\NP)\(S\NP))/NP 	 3 	 study in
33 	 32 	 NP[nb]/N 	 1 	 study a
33 	 34 	 (NP\NP)/NP 	 1 	 study of
33 	 37 	 (NP\NP)/(S[dcl]\NP) 	 1 	 study that
33 	 38 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 study has <XB>
33 	 39 	 (S[pt]\NP)/PP 	 1 	 study been <XB>
36 	 34 	 (NP\NP)/NP 	 2 	 diabetics of
36 	 35 	 N/N 	 1 	 diabetics 1,500
38 	 37 	 (NP\NP)/(S[dcl]\NP) 	 2 	 has that
39 	 38 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been has
39 	 42 	 ((S\NP)\(S\NP))/NP 	 2 	 been at
39 	 44 	 ((S\NP)\(S\NP))/NP 	 2 	 been for
40 	 39 	 (S[pt]\NP)/PP 	 2 	 under been
41 	 40 	 PP/NP 	 1 	 way under
43 	 42 	 ((S\NP)\(S\NP))/NP 	 3 	 NIH at
46 	 44 	 ((S\NP)\(S\NP))/NP 	 3 	 years for
46 	 45 	 N/N 	 1 	 years five
<\s>
<s id="wsj_0690.12"> 20
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 he said
3 	 0 	 S/S 	 1 	 said However
4 	 5 	 (S[ng]\NP)/NP 	 1 	 officials conducting <XB>
4 	 8 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 officials had
4 	 11 	 (S[ng]\NP)/PP 	 1 	 officials looking <XB>
7 	 5 	 (S[ng]\NP)/NP 	 2 	 study conducting
7 	 6 	 NP[nb]/N 	 1 	 study the
8 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 had said
8 	 9 	 (S\NP)\(S\NP) 	 2 	 had n't
10 	 8 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been had
11 	 10 	 (S[pt]\NP)/(S[ng]\NP) 	 2 	 looking been
12 	 11 	 (S[ng]\NP)/PP 	 2 	 for looking
13 	 12 	 PP/NP 	 1 	 signs for
13 	 14 	 (NP\NP)/NP 	 1 	 signs of
15 	 14 	 (NP\NP)/NP 	 2 	 problems of
15 	 16 	 S[adj]\NP 	 1 	 problems related <XB>
16 	 17 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 2 	 related to
19 	 17 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 3 	 unawareness to
19 	 18 	 N/N 	 1 	 unawareness hypoglycemia
<\s>
<s id="wsj_0690.13"> 12
0 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 We are
0 	 3 	 (S[ng]\NP)/PP 	 1 	 We monitoring <XB>
1 	 2 	 (S\NP)\(S\NP) 	 2 	 are now
1 	 11 	 (S[dcl]\S[dcl])\NP 	 1 	 are said
3 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 monitoring are
3 	 8 	 (S\NP)\(S\NP) 	 2 	 monitoring closely
4 	 3 	 (S[ng]\NP)/PP 	 2 	 for monitoring
5 	 4 	 PP/NP 	 1 	 it for
8 	 6 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 closely much
8 	 7 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 closely more
10 	 11 	 (S[dcl]\S[dcl])\NP 	 2 	 he said
<\s>
<s id="wsj_0690.14"> 22
0 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 We do
0 	 2 	 (S[b]\NP)/S[dcl] 	 1 	 We know <XB>
1 	 21 	 (S[dcl]\S[dcl])\NP 	 1 	 do said
2 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 know do
3 	 4 	 (S[dcl]\NP[thr])/NP 	 1 	 there are
4 	 2 	 (S[b]\NP)/S[dcl] 	 2 	 are know
6 	 4 	 (S[dcl]\NP[thr])/NP 	 2 	 differences are
6 	 5 	 N/N 	 1 	 differences slight
6 	 7 	 (NP\NP)/NP 	 1 	 differences in
9 	 7 	 (NP\NP)/NP 	 2 	 way in
9 	 8 	 NP[nb]/N 	 1 	 way the
13 	 10 	 N/N 	 1 	 insulins human <XU>
13 	 12 	 N/N 	 1 	 insulins animal
13 	 14 	 (S[dcl]\NP)/NP 	 1 	 insulins drive
14 	 15 	 (S\NP)\(S\NP) 	 2 	 drive down
17 	 14 	 (S[dcl]\NP)/NP 	 2 	 sugar drive
17 	 16 	 N/N 	 1 	 sugar blood
20 	 19 	 N/N 	 1 	 Sobel Dr.
20 	 21 	 (S[dcl]\S[dcl])\NP 	 2 	 Sobel said
<\s>
<s id="wsj_0690.15"> 17
2 	 0 	 NP[nb]/N 	 1 	 drug The
2 	 1 	 N/N 	 1 	 drug human-based
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 drug starts
2 	 10 	 (S[dcl]\NP)/NP 	 1 	 drug drives <XU>
3 	 8 	 (S\NP)\(S\NP) 	 2 	 starts sooner
3 	 16 	 (S[dcl]\S[dcl])\NP 	 1 	 starts said
7 	 3 	 (S[dcl]\NP)/NP 	 2 	 dropping starts
7 	 4 	 NP[nb]/N 	 1 	 dropping the
7 	 5 	 N/N 	 1 	 dropping blood
7 	 6 	 N/N 	 1 	 dropping sugar
10 	 12 	 (S\NP)\(S\NP) 	 2 	 drives down
10 	 13 	 (S\NP)\(S\NP) 	 2 	 drives faster
10 	 16 	 (S[dcl]\S[dcl])\NP 	 1 	 drives said
11 	 10 	 (S[dcl]\NP)/NP 	 2 	 it drives
15 	 16 	 (S[dcl]\S[dcl])\NP 	 2 	 he said
<\s>
<s id="wsj_0690.16"> 19
1 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 we do
1 	 4 	 (S[b]\NP)/S[dcl] 	 1 	 we believe <XB>
2 	 0 	 S/S 	 1 	 do But
2 	 3 	 (S\NP)\(S\NP) 	 2 	 do n't
2 	 18 	 (S[dcl]\S[dcl])\NP 	 1 	 do said
4 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 believe do
5 	 6 	 (S[dcl]\NP[thr])/(S[adj]\NP) 	 1 	 there is
6 	 4 	 (S[b]\NP)/S[dcl] 	 2 	 is believe
7 	 6 	 (S[dcl]\NP[thr])/(S[adj]\NP) 	 2 	 enough is
8 	 7 	 ((S[adj]\NP)/(S[to]\NP))/PP 	 3 	 of enough
10 	 8 	 PP/NP 	 1 	 difference of
10 	 9 	 NP[nb]/N 	 1 	 difference a
11 	 7 	 ((S[adj]\NP)/(S[to]\NP))/PP 	 2 	 to enough
12 	 11 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
14 	 12 	 (S[b]\NP)/(S[adj]\NP) 	 2 	 significant be
14 	 13 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 significant clinically
17 	 16 	 N/N 	 1 	 Sobel Dr.
17 	 18 	 (S[dcl]\S[dcl])\NP 	 2 	 Sobel said
<\s>
<s id="wsj_0690.17"> 17
0 	 1 	 (NP\NP)/NP 	 1 	 Reports of
0 	 6 	 (NP\NP)/NP 	 1 	 Reports in
0 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 Reports have
0 	 11 	 (S[pt]\NP)/NP 	 1 	 Reports triggered <XB>
3 	 2 	 N/N 	 1 	 Toseland Dr.
3 	 4 	 (NP[nb]/N)\NP 	 2 	 Toseland 's
5 	 1 	 (NP\NP)/NP 	 2 	 findings of
5 	 4 	 (NP[nb]/N)\NP 	 1 	 findings 's
9 	 6 	 (NP\NP)/NP 	 2 	 press in
9 	 7 	 NP[nb]/N 	 1 	 press the
9 	 8 	 N/N 	 1 	 press British
11 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 triggered have
11 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 triggered among
13 	 11 	 (S[pt]\NP)/NP 	 2 	 concern triggered
13 	 12 	 N/N 	 1 	 concern widespread
15 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 diabetics among
15 	 16 	 NP\NP 	 1 	 diabetics there
<\s>
<s id="wsj_0690.18"> 37
4 	 0 	 NP/NP 	 1 	 Association Both
4 	 1 	 NP[nb]/N 	 1 	 Association the
4 	 2 	 N/N 	 1 	 Association British
4 	 3 	 N/N 	 1 	 Association Diabetic
4 	 22 	 (S[dcl]\NP)/NP 	 1 	 Association issued
7 	 0 	 NP/NP 	 1 	 Committee Both
7 	 6 	 NP[nb]/N 	 1 	 Committee the
7 	 8 	 (NP\NP)/NP 	 1 	 Committee on
7 	 12 	 (NP\NP)/NP 	 1 	 Committee --
7 	 22 	 (S[dcl]\NP)/NP 	 1 	 Committee issued
9 	 8 	 (NP\NP)/NP 	 2 	 Safety on
9 	 10 	 (NP\NP)/NP 	 1 	 Safety in
11 	 10 	 (NP\NP)/NP 	 2 	 Medicines in
13 	 14 	 (NP[nb]/N)\NP 	 2 	 Britain 's
15 	 12 	 (NP\NP)/NP 	 2 	 equivalent --
15 	 14 	 (NP[nb]/N)\NP 	 1 	 equivalent 's
15 	 16 	 (NP\NP)/NP 	 1 	 equivalent of
19 	 16 	 (NP\NP)/NP 	 2 	 FDA of
19 	 17 	 NP[nb]/N 	 1 	 FDA the
19 	 18 	 N/N 	 1 	 FDA U.S.
22 	 21 	 (S\NP)/(S\NP) 	 2 	 issued recently
23 	 22 	 (S[dcl]\NP)/NP 	 2 	 statements issued
23 	 24 	 (S[ng]\NP)/NP 	 1 	 statements noting <XB>
26 	 24 	 (S[ng]\NP)/NP 	 2 	 lack noting
26 	 25 	 NP[nb]/N 	 1 	 lack the
26 	 27 	 (NP\NP)/NP 	 1 	 lack of
30 	 27 	 (NP\NP)/NP 	 2 	 evidence of
30 	 28 	 N/N 	 1 	 evidence hard
30 	 29 	 N/N 	 1 	 evidence scientific
32 	 31 	 (S[to]\NP)/(S[b]\NP) 	 2 	 support to
34 	 33 	 N/N 	 1 	 Toseland Dr.
34 	 35 	 (NP[nb]/N)\NP 	 2 	 Toseland 's
36 	 32 	 (S[b]\NP)/NP 	 2 	 findings support
36 	 35 	 (NP[nb]/N)\NP 	 1 	 findings 's
<\s>
<s id="wsj_0690.19"> 24
1 	 0 	 (S/S)/NP 	 2 	 Friday On
6 	 3 	 NP[nb]/N 	 1 	 Association the
6 	 4 	 N/N 	 1 	 Association American
6 	 5 	 N/N 	 1 	 Association Diabetes
6 	 7 	 (S[dcl]\NP)/NP 	 1 	 Association issued
7 	 0 	 (S/S)/NP 	 1 	 issued On
10 	 7 	 (S[dcl]\NP)/NP 	 2 	 statement issued
10 	 8 	 NP[nb]/N 	 1 	 statement a
10 	 9 	 N/N 	 1 	 statement similar
10 	 11 	 ((S[ng]\NP)/(S[to]\NP))/NP 	 1 	 statement urging <XB>
14 	 13 	 (N/N)/(N/N) 	 2 	 million six
16 	 11 	 ((S[ng]\NP)/(S[to]\NP))/NP 	 3 	 diabetics urging
16 	 12 	 NP[nb]/N 	 1 	 diabetics the
16 	 14 	 N/N 	 1 	 diabetics million
16 	 15 	 N/N 	 1 	 diabetics U.S.
16 	 19 	 (S[b]\NP)/PP 	 1 	 diabetics overreact <XB>
18 	 11 	 ((S[ng]\NP)/(S[to]\NP))/NP 	 2 	 to urging
18 	 17 	 (S\NP)/(S\NP) 	 2 	 to not
19 	 18 	 (S[to]\NP)/(S[b]\NP) 	 2 	 overreact to
20 	 19 	 (S[b]\NP)/PP 	 2 	 to overreact
23 	 20 	 PP/NP 	 1 	 report to
23 	 21 	 NP[nb]/N 	 1 	 report the
23 	 22 	 N/N 	 1 	 report British
<\s>
<s id="wsj_0690.20"> 31
1 	 0 	 NP[nb]/N 	 1 	 loss A
1 	 2 	 (NP\NP)/NP 	 1 	 loss of
1 	 8 	 (S[dcl]\NP)/NP 	 1 	 loss is
5 	 2 	 (NP\NP)/NP 	 2 	 symptoms of
5 	 3 	 NP[nb]/N 	 1 	 symptoms the
5 	 4 	 N/N 	 1 	 symptoms warning
5 	 6 	 (NP\NP)/NP 	 1 	 symptoms of
7 	 6 	 (NP\NP)/NP 	 2 	 hypoglycemia of
8 	 30 	 (S[dcl]\S[dcl])\NP 	 1 	 is said
11 	 8 	 (S[dcl]\NP)/NP 	 2 	 problem is
11 	 9 	 NP[nb]/N 	 1 	 problem a
11 	 10 	 N/N 	 1 	 problem complex
11 	 12 	 (NP\NP)/(S[dcl]\NP) 	 1 	 problem that
11 	 13 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 problem is <XB>
11 	 15 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 problem unlikely <XB>
13 	 12 	 (NP\NP)/(S[dcl]\NP) 	 2 	 is that
15 	 13 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 unlikely is
15 	 14 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 unlikely very
16 	 15 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to unlikely
17 	 16 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
18 	 17 	 (S[b]\NP)/(S[adj]\NP) 	 2 	 due be
20 	 18 	 (S[adj]\NP)/PP 	 2 	 to due
20 	 19 	 PP/PP 	 1 	 to simply
22 	 20 	 PP/NP 	 1 	 type to
22 	 21 	 NP[nb]/N 	 1 	 type the
22 	 23 	 (NP\NP)/NP 	 1 	 type of
22 	 25 	 S[pss]\NP 	 1 	 type used <XB>
24 	 23 	 (NP\NP)/NP 	 2 	 insulin of
29 	 27 	 NP[nb]/N 	 1 	 association the
29 	 28 	 N/N 	 1 	 association American
29 	 30 	 (S[dcl]\S[dcl])\NP 	 2 	 association said
<\s>
<s id="wsj_0690.21"> 26
1 	 0 	 NP[nb]/N 	 1 	 FDA The
1 	 3 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 1 	 FDA requires
3 	 2 	 (S\NP)/(S\NP) 	 2 	 requires already
5 	 3 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 3 	 manufacturers requires
5 	 4 	 N/N 	 1 	 manufacturers drug
5 	 7 	 ((S[b]\NP)/PP)/NP 	 1 	 manufacturers include <XB>
6 	 3 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 2 	 to requires
7 	 6 	 (S[to]\NP)/(S[b]\NP) 	 2 	 include to
7 	 12 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 include that
8 	 7 	 ((S[b]\NP)/PP)/NP 	 3 	 warnings include
9 	 7 	 ((S[b]\NP)/PP)/NP 	 2 	 with include
11 	 9 	 PP/NP 	 1 	 products with
11 	 10 	 N/N 	 1 	 products insulin
13 	 14 	 (NP\NP)/NP 	 1 	 symptoms of
13 	 16 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 symptoms are
13 	 18 	 (S[adj]\NP)/PP 	 1 	 symptoms pronounced <XB>
15 	 14 	 (NP\NP)/NP 	 2 	 hypoglycemia of
16 	 12 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 are that
18 	 16 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 pronounced are
18 	 17 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 pronounced less
18 	 22 	 ((S[adj]\NP)\(S[adj]\NP))/PP 	 2 	 pronounced than
19 	 18 	 (S[adj]\NP)/PP 	 2 	 with pronounced
21 	 19 	 PP/NP 	 1 	 insulin with
21 	 20 	 N/N 	 1 	 insulin human
23 	 22 	 ((S[adj]\NP)\(S[adj]\NP))/PP 	 3 	 with than
25 	 23 	 PP/NP 	 1 	 products with
25 	 24 	 N/N 	 1 	 products animal-based
<\s>
<s id="wsj_0690.22"> 22
3 	 0 	 N/N 	 1 	 Co. Eli
3 	 1 	 N/N 	 1 	 Co. Lilly
3 	 2 	 N/N 	 1 	 Co. &
3 	 10 	 (S[dcl]\NP)/NP 	 1 	 Co. dominates
8 	 5 	 NP[nb]/N 	 1 	 manufacturer the
8 	 6 	 N/N 	 1 	 manufacturer Indianapolis-based
8 	 7 	 N/N 	 1 	 manufacturer drug
8 	 10 	 (S[dcl]\NP)/NP 	 1 	 manufacturer dominates
10 	 16 	 ((S\NP)\(S\NP))/NP 	 2 	 dominates with
15 	 10 	 (S[dcl]\NP)/NP 	 2 	 market dominates
15 	 11 	 NP[nb]/N 	 1 	 market the
15 	 12 	 N/N 	 1 	 market U.S.
15 	 13 	 N/N 	 1 	 market human
15 	 14 	 N/N 	 1 	 market insulin
18 	 16 	 ((S\NP)\(S\NP))/NP 	 3 	 product with
18 	 17 	 NP[nb]/N 	 1 	 product its
18 	 19 	 (S[pss]\NP)/PP 	 1 	 product known <XB>
20 	 19 	 (S[pss]\NP)/PP 	 2 	 as known
21 	 20 	 PP/NP 	 1 	 Humulin as
<\s>
<s id="wsj_0690.23"> 14
0 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 Lilly is
0 	 2 	 (S[ng]\NP)/NP 	 1 	 Lilly building <XB>
2 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 building is
2 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 building in
3 	 2 	 (S[ng]\NP)/NP 	 2 	 plants building
5 	 4 	 (S[to]\NP)/(S[b]\NP) 	 2 	 make to
7 	 5 	 (S[b]\NP)/NP 	 2 	 insulin make
7 	 6 	 NP[nb]/N 	 1 	 insulin the
9 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 Indianapolis in
11 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 Fagershein in
11 	 13 	 NP\NP 	 1 	 Fagershein France
<\s>
<s id="wsj_0690.24"> 14
4 	 0 	 (S/S)/NP 	 2 	 report In
4 	 1 	 NP[nb]/N 	 1 	 report its
4 	 2 	 N/N 	 1 	 report latest
4 	 3 	 N/N 	 1 	 report annual
6 	 7 	 (S[dcl]\NP)/S[dcl] 	 1 	 Lilly said
7 	 0 	 (S/S)/NP 	 1 	 said In
9 	 8 	 N/N 	 1 	 sales Humulin
9 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 sales have
9 	 11 	 (S[pt]\NP)/NP 	 1 	 sales shown <XB>
10 	 7 	 (S[dcl]\NP)/S[dcl] 	 2 	 have said
11 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 shown have
13 	 11 	 (S[pt]\NP)/NP 	 2 	 growth shown
13 	 12 	 N/N 	 1 	 growth excellent
<\s>
<s id="wsj_0690.25"> 33
1 	 0 	 N/N 	 1 	 officials Lilly
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 officials said
1 	 23 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 officials did <XU>
1 	 25 	 (S[b]\NP)/S[qem] 	 1 	 officials know <XU>
3 	 4 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 they had
3 	 5 	 (S[pt]\NP)/NP 	 1 	 they seen <XB>
4 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 had said
5 	 4 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 seen had
6 	 5 	 (S[pt]\NP)/NP 	 2 	 reports seen
6 	 7 	 (NP\NP)/NP 	 1 	 reports of
9 	 7 	 (NP\NP)/NP 	 2 	 unawareness of
9 	 8 	 N/N 	 1 	 unawareness hypoglycemic
9 	 10 	 (NP\NP)/NP 	 1 	 unawareness among
12 	 10 	 (NP\NP)/NP 	 2 	 patients among
12 	 11 	 NP[nb]/N 	 1 	 patients some
12 	 13 	 (S[ng]\NP)/NP 	 1 	 patients making <XB>
15 	 13 	 (S[ng]\NP)/NP 	 2 	 shift making
15 	 14 	 NP[nb]/N 	 1 	 shift the
15 	 16 	 (NP\NP)/(S[adj]\NP) 	 1 	 shift from
15 	 18 	 (NP\NP)/NP 	 1 	 shift to
17 	 16 	 (NP\NP)/(S[adj]\NP) 	 2 	 animal from
20 	 18 	 (NP\NP)/NP 	 2 	 insulin to
20 	 19 	 N/N 	 1 	 insulin human
23 	 24 	 (S\NP)\(S\NP) 	 2 	 did n't
25 	 23 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 know did
26 	 25 	 (S[b]\NP)/S[qem] 	 2 	 if know
28 	 27 	 NP[nb]/N 	 1 	 problem the
28 	 29 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 problem had
28 	 30 	 (S[pt]\NP)/NP 	 1 	 problem caused <XB>
29 	 26 	 S[qem]/S[dcl] 	 1 	 had if
30 	 29 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 caused had
32 	 30 	 (S[pt]\NP)/NP 	 2 	 deaths caused
32 	 31 	 NP[nb]/N 	 1 	 deaths any
<\s>
<s id="wsj_0690.26"> 36
2 	 0 	 N/N 	 1 	 Thompson Dr.
2 	 1 	 N/N 	 1 	 Thompson Leigh
2 	 10 	 (S[dcl]\NP)/S[dcl] 	 1 	 Thompson said
8 	 4 	 NP[nb]/N 	 1 	 president a
8 	 5 	 N/N 	 1 	 president Lilly
8 	 6 	 N/N 	 1 	 president group
8 	 7 	 N/N 	 1 	 president vice
8 	 10 	 (S[dcl]\NP)/S[dcl] 	 1 	 president said
12 	 11 	 NP[nb]/N 	 1 	 company the
12 	 13 	 (NP[nb]/N)\NP 	 2 	 company 's
15 	 13 	 (NP[nb]/N)\NP 	 1 	 trials 's
15 	 14 	 N/N 	 1 	 trials clinical
15 	 16 	 (NP\NP)/NP 	 1 	 trials of
15 	 23 	 (S[dcl]\NP)/NP 	 1 	 trials indicated
22 	 16 	 (NP\NP)/NP 	 2 	 insulins of
22 	 17 	 NP/NP 	 1 	 insulins both
22 	 18 	 NP[nb]/N 	 1 	 insulins its
22 	 19 	 N/N 	 1 	 insulins animal <XU>
22 	 21 	 N/N 	 1 	 insulins human-based
23 	 10 	 (S[dcl]\NP)/S[dcl] 	 2 	 indicated said
25 	 23 	 (S[dcl]\NP)/NP 	 2 	 difference indicated
25 	 24 	 NP[nb]/N 	 1 	 difference no
25 	 26 	 (NP\NP)/NP 	 1 	 difference in
25 	 31 	 (NP\NP)/NP 	 1 	 difference between
28 	 26 	 (NP\NP)/NP 	 2 	 level in
28 	 27 	 NP[nb]/N 	 1 	 level the
28 	 29 	 (NP\NP)/NP 	 1 	 level of
30 	 29 	 (NP\NP)/NP 	 2 	 hypoglycemia of
32 	 31 	 (NP\NP)/NP 	 2 	 users between
32 	 33 	 (NP\NP)/NP 	 1 	 users of
35 	 33 	 (NP\NP)/NP 	 2 	 product of
35 	 34 	 NP[nb]/N 	 1 	 product either
<\s>
<s id="wsj_0690.27"> 23
1 	 0 	 N/N 	 1 	 Toseland Dr.
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Toseland said
3 	 4 	 (NP\NP)/NP 	 1 	 most of
3 	 8 	 (NP\NP)/(S[dcl]\NP) 	 1 	 most who
3 	 9 	 S[dcl]\NP 	 1 	 most died <XB>
3 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 most had
3 	 12 	 (S[ng]\NP)/NP 	 1 	 most taking <XB>
7 	 4 	 (NP\NP)/NP 	 2 	 diabetics of
7 	 5 	 NP[nb]/N 	 1 	 diabetics the
7 	 6 	 N/N 	 1 	 diabetics British
9 	 8 	 (NP\NP)/(S[dcl]\NP) 	 2 	 died who
10 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 had said
11 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been had
12 	 11 	 (S[pt]\NP)/(S[ng]\NP) 	 2 	 taking been
15 	 12 	 (S[ng]\NP)/NP 	 2 	 insulin taking
15 	 13 	 NP[nb]/N 	 1 	 insulin a
15 	 14 	 N/N 	 1 	 insulin human-based
15 	 16 	 S[pss]\NP 	 1 	 insulin made <XB>
16 	 17 	 ((S\NP)\(S\NP))/NP 	 2 	 made by
18 	 17 	 ((S\NP)\(S\NP))/NP 	 3 	 Novo\/Nordisk by
22 	 17 	 ((S\NP)\(S\NP))/NP 	 3 	 manufacturer by
22 	 20 	 NP[nb]/N 	 1 	 manufacturer a
22 	 21 	 N/N 	 1 	 manufacturer Danish
<\s>
<s id="wsj_0690.28"> 9
0 	 1 	 (NP\NP)/NP 	 1 	 None of
0 	 4 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 None were
0 	 5 	 (S[ng]\NP)/NP 	 1 	 None using <XB>
3 	 1 	 (NP\NP)/NP 	 2 	 diabetics of
3 	 2 	 NP[nb]/N 	 1 	 diabetics the
5 	 4 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 using were
6 	 7 	 (NP[nb]/N)\NP 	 2 	 Lilly 's
8 	 5 	 (S[ng]\NP)/NP 	 2 	 insulin using
8 	 7 	 (NP[nb]/N)\NP 	 1 	 insulin 's
<\s>
